Formal proposal? Tyva's official acquisition of mylan this week or $43 billion
-
Last Update: 2015-07-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: last July 2015-7, Robert Coury, chairman of mylan, stormed and asked Teva to either make a formal offer or stand aside to continue the marriage of Perrigo It's like a woman pointing at a man's nose and cursing You either formally propose or get out of the way Don't stop my mother from pursuing her happiness! Perhaps courry's will will will come true as soon as this week (related reading: rumors come true! In April this year, TIWA, the world's largest generic manufacturer, proposed a $40 billion acquisition plan to us competitor Meilan, offering a 21% premium of $82 per share, but was rejected by Meilan Recently, Bloomberg revealed that the Israeli pharmaceutical giant was ready to raise its offer, from the initial $82 per share to $86 to $88 per share, with a total price of $43 billion TIWA is likely to make the formal offer as soon as this week, sources said TIWA has previously said that as long as mylan is willing to marry, the price is not a problem Meilan insists that TIWA is not his favorite target If TIWA is determined to launch a hostile takeover, he must be prepared for several years of World War I However, in TIWA's view, mylan should not treat its investors in this way The company refused to negotiate with TIWA but at the same time continued to push forward the merger with Briggs & noble, which actually put its shareholders in a difficult situation Therefore, TIWA intends to let investors choose for themselves, and a formal offer will provide investors with a choice to consider TIWA hopes that before the formal meeting of the two sides this summer, shareholders of mylan will vote on the acquisition of Briggs & Noble In fact, while mylan firmly resisted the TIWA acquisition, Briggs & Gamble did not show too much excitement about mylan's acquisition intention The Irish drugmaker has rejected the offer offered by mylan three times in a row, saying its offer clearly undervalued the company.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.